Display options
Cite
Khat'kova SE, Baikova A, Maisonobe P, et al. Vliyanie kompleksnogo lecheniya spastichnosti verkhnei konechnosti, vklyuchayushchego povtornye in"ektsii botulinicheskogo toksina tipa A, na dostizhenie tselei, orientirovannykh na nuzhdy patsienta, v real'noi klinicheskoi praktike: rezul'taty mezhdunarodnogo prospektivnogo, nablyudatel'nogo issledovaniya spastichnosti verkhnei konechnosti ULIS-III v rossiiskoi podgruppe patsientov. [Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(11):39-48doi: 10.17116/jnevro202112111139.
Khat'kova, S. E., Baikova, A., Maisonobe, P., & Khasanova, D. R. (2021). Vliyanie kompleksnogo lecheniya spastichnosti verkhnei konechnosti, vklyuchayushchego povtornye in"ektsii botulinicheskogo toksina tipa A, na dostizhenie tselei, orientirovannykh na nuzhdy patsienta, v real'noi klinicheskoi praktike: rezul'taty mezhdunarodnogo prospektivnogo, nablyudatel'nogo issledovaniya spastichnosti verkhnei konechnosti ULIS-III v rossiiskoi podgruppe patsientov. [Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 121(11), 39-48. https://doi.org/10.17116/jnevro202112111139
Khat'kova, S E, et al. "Vliyanie kompleksnogo lecheniya spastichnosti verkhnei konechnosti, vklyuchayushchego povtornye in"ektsii botulinicheskogo toksina tipa A, na dostizhenie tselei, orientirovannykh na nuzhdy patsienta, v real'noi klinicheskoi praktike: rezul'taty mezhdunarodnogo prospektivnogo, nablyudatel'nogo issledovaniya spastichnosti verkhnei konechnosti ULIS-III v rossiiskoi podgruppe patsientov." [Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 121,11 (2021): 39-48. doi: https://doi.org/10.17116/jnevro202112111139
Khat'kova SE, Baikova A, Maisonobe P, Khasanova DR. Vliyanie kompleksnogo lecheniya spastichnosti verkhnei konechnosti, vklyuchayushchego povtornye in"ektsii botulinicheskogo toksina tipa A, na dostizhenie tselei, orientirovannykh na nuzhdy patsienta, v real'noi klinicheskoi praktike: rezul'taty mezhdunarodnogo prospektivnogo, nablyudatel'nogo issledovaniya spastichnosti verkhnei konechnosti ULIS-III v rossiiskoi podgruppe patsientov. [Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(11):39-48. doi: 10.17116/jnevro202112111139. Russian. PMID: 34932284.
Copy Download .nbib Format: NLM
Share it on

Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(11):39-48. doi: 10.17116/jnevro202112111139.

[Impact of integrated upper limb spasticity management including repeat botulinum toxin type A (BoNT-A) injections on patient-centred goal attainment in real-life practice: results from the prospective, observational Upper Limb International Spasticity cohort study (ULIS-III) in a Russian subpopulation].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Article in Russian]
S E Khat'kova, A Baikova, P Maisonobe, D R Khasanova

Affiliations

  1. National Medical Research Center «Treatment and Rehabilitation Center», Moscow, Russia.
  2. Medical Affairs, Ipsen Pharma, Moscow, Russia.
  3. Department of Biometry Ipsen Pharma, Boulogne-Billancourt, France.
  4. Interregional Clinical and Diagnostic Center, Kazan, Russia.

PMID: 34932284 DOI: 10.17116/jnevro202112111139

Abstract

OBJECTIVE: To assess the longitudinal attainment of patient-centred and function related goals after integrated spasticity management including repeated cycles of botulinum toxin A type A (BoNT-A) injections in real life settings over a period of 2 years. The article presents analysis of the results within the subpopulation of patients from Russia.

MATERIAL AND METHODS: This international, multicentre, observational, prospective, longitudinal cohort study (registered at clinicaltrials.gov as NCT02454803) included patients ≥18 years old with upper-limb spasticity of any aetiology in whom a decision had already been made to inject any BoNT-A formulation commercially available in the Russi. The treatment outcomes were evaluated using the Upper Limb Spasticity Index, which combines the patient-centred Goal Attainment Scaling (GAS) with a set of targeted standardised measures to assess the neurological impairment. The extent of functional impairment was assessed using the DAS.

RESULTS: 168 Russian patients from 7 sites with a mean age of 49.8 years participated in the study. The Russian subpopulation had some differences from the overall study population in baseline characteristics of patients and injection practices of BoNT-A treatment. During the study period, the majority of Russian patients received AboBoNT-A (Dysport) injections - 142 (85%) patients at cycle 1, while OnaBoNT-A (Botox) was used in 14 (8%) patients, and IncoBoNT-A (Xeomin) - in 12 (7%) patients. Higher doses of AboBoNT-A were observed compared to the overall population, mean doses of AboBoNT-A between cycles 1 and 4 were 909-934 U in the Russian patients and 814-859 U in the overall population. In general, patients of the Russian subpopulation successfully achieved their treatment goals. The mean cumulated GAS T-score over the study was 51.1±3.0, marginally exceeding the same parameter in the overall population (49.5±5.9). Across the 6 goal domains, cumulated GAS T-scores in Russian subpopulation were highest for the goals related to passive function and pain relief, with mean scores of 51.8±4.2 and 51.6±4.8, respectively. In the overall population cumulated GAS T-scores were highest for involuntary movements (mean 50.5±5.6) and pain relief (mean 50.4±6.2). The lowest GAS T-scores were for the treatment goals related to active function in both Russian subpopulation and overall population, the mean scores were 48.3±5.5 and 46.6±7.4 respectively. The study results also showed significant improvement in in terms of reduction of muscle tone according to MAS (Modified Ashworth Scale) and the extent of functional impairment according to DAS (Disability Assessment Scale).

CONCLUSIONS: The results of this subgroup analysis on patients from Russia showed high effectiveness of repeated cycles of BoNT-A injections as part of the integrated upper limb spasticity management conducted in real life settings, both in terms of reduction of muscle tone and correction of functional impairment, which contributes to the successful achievement of the treatment goals. The right choice of individual patient-centred treatment goals and methods for assessing their achievement are important components of the treatment and rehabilitation process for patients with spastic paresis of the upper limb.

Keywords: Abobotulinumtoxin-A; Incobotulinumtoxin-A; Onabotulinumtoxin-A; botulinum-toxin therapy; goal attainment scaling (GAS); upper limb spasticity

Publication Types